Literature DB >> 12641511

Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome.

R Lea1, L A Houghton, E L Calvert, S Larder, W M Gonsalkorale, V Whelan, J Randles, P Cooper, P Cruickshanks, V Miller, P J Whorwell.   

Abstract

BACKGROUND: We have previously shown that hypnotherapy alters rectal sensitivity in some patients with irritable bowel syndrome. However, this previous study used incremental volume distension of a latex balloon, which might be susceptible to subject response bias and might compromise the assessment of compliance. In addition, the study group was symptomatically rather than physiologically defined. AIM: To assess the effect of hypnotherapy on rectal sensitivity in hypersensitive, hyposensitive and normally sensitive irritable bowel syndrome patients using a distension technique (barostat) that addresses these technical issues.
METHODS: Twenty-three irritable bowel syndrome (Rome I) patients (aged 24-72 years) were assessed before and after 12 weeks of hypnotherapy in terms of rectal sensitivity, symptomatology, anxiety and depression. Normal values for sensitivity were established in 17 healthy volunteers (aged 20-55 years).
RESULTS: Compared with controls, 10 patients were hypersensitive, seven hyposensitive and six normally sensitive before treatment. Following hypnotherapy, the mean pain sensory threshold increased in the hypersensitive group (P = 0.04) and decreased in the hyposensitive group, although the latter failed to reach statistical significance (P = 0.19). Normal sensory perception was unchanged. Sensory improvement in the hypersensitive patients tended to correlate with a reduction in abdominal pain (r = 0.714, P = 0.07).
CONCLUSION: Hypnotherapy improves abnormal sensory perception in irritable bowel syndrome, leaving normal sensation unchanged.

Entities:  

Mesh:

Year:  2003        PMID: 12641511     DOI: 10.1046/j.1365-2036.2003.01486.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

1.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

2.  Bloating and intestinal gas.

Authors:  Michael P Jones
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

3.  Hypnosis for non-cardiac chest pain.

Authors:  O S Palsson; W E Whitehead
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

4.  Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy.

Authors:  H Jones; P Cooper; V Miller; N Brooks; P J Whorwell
Journal:  Gut       Date:  2006-04-20       Impact factor: 23.059

Review 5.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

Review 6.  Hypnosis and upper digestive function and disease.

Authors:  Giuseppe Chiarioni; Olafur S Palsson; William E Whitehead
Journal:  World J Gastroenterol       Date:  2008-11-07       Impact factor: 5.742

7.  Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis.

Authors:  L Keefer; T H Taft; J L Kiebles; Z Martinovich; T A Barrett; O S Palsson
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

8.  Hypnotherapy for Esophageal Disorders.

Authors:  Megan E Riehl; Laurie Keefer
Journal:  Am J Clin Hypn       Date:  2015-07

9.  Role of a health psychologist in the management of functional esophageal complaints.

Authors:  M E Riehl; S Kinsinger; P J Kahrilas; J E Pandolfino; L Keefer
Journal:  Dis Esophagus       Date:  2014-04-03       Impact factor: 3.429

10.  Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome.

Authors:  M B O Lowén; E A Mayer; M Sjöberg; K Tillisch; B Naliboff; J Labus; P Lundberg; M Ström; M Engström; S A Walter
Journal:  Aliment Pharmacol Ther       Date:  2013-04-25       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.